Found 170 articles for: "ustekinumab"
Biologic Use During Pregnancy and Breastfeeding in Dermatology: An Evidence-Based Review
November 2024 | Volume 23 | Issue 11 | Original Article | 1010 | Copyright © November 2024
Biologic medications have revolutionized the treatment of many dermatologic conditions. However, their use during pregnancy and breastfeeding is a subject of ongoing concern due to limited data o...
Read MoreStructural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis
October 2024 | Volume 23 | Issue 10 | Features | 903 | Copyright © October 2024
Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 645 | Copyright © August 2024
Members of the Janus kinase (JAK) superfamily, comprising tyrosine kinase 2 (TYK2) and JAK1, JAK2, and JAK3, mediate signaling by cytokines (eg, interleukin [IL]-23) involved in psoriasis pathoge...
Read MoreSafety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
August 2024 | Volume 23 | Issue 8 | Original Article | 592 | Copyright © August 2024
Background: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target bot...
Read MoreEfficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients with Skin Phototypes IV to VI
August 2024 | Volume 23 | Issue 8 | Original Article | 600 | Copyright © August 2024
Background: There is a paucity of data on the treatment of psoriasis in patients with skin of color – a diverse population among whom variations in clinical features and hi...
Read MoreReal-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study
August 2024 | Volume 23 | Issue 8 | Original Article | 632 | Copyright © August 2024
Background: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-...
Read MoreRapid Remission of Plaque Psoriasis With Bimekizumab Treatment
August 2024 | Volume 23 | Issue 8 | Features | 694 | Copyright © August 2024
Bimekizumab is a novel humanized bispecific monoclonal immunoglobulin G1 (IgG1) antibody that dually inhibits both IL-17A and IL-17F. Investigation of the pivotal role of IL-17A, and more recentl...
Read MoreRecalcitrant Erythrodermic Psoriasis Complicated by Septic Shock and Mycotic Aneurysm: A Call for Treatment Guidelines
August 2024 | Volume 23 | Issue 8 | Case Reports | 680 | Copyright © August 2024
Erythroderma is characterized by diffuse erythema and scale covering over 90% body surface area that can affect individuals with inflammatory dermatoses such as psoriasis. Complications of erythr...
Read MorePalmoplantar Pustulosis: Therapy Update
August 2024 | Volume 23 | Issue 8 | Original Article | 626 | Copyright © August 2024
Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic ...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Background: Biologics have shown promising outcomes in psoriasis clinical trials. However, there is a paucity of data exploring the potential differences in outcomes between self...
Read MoreBlood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 74 | Copyright © February 2024
Early response to treatment with biologics, defined as Psoriasis Area and Severity Index (PASI) of 2 or less six months after initiation of therapy, seems to be associated with more stable psoria...
Read MoreA Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
February 2024 | Volume 23 | Issue 2 | Case Reports | e60 | Copyright © February 2024
Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), spondyloarthriti...
Read MoreOff-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreIndividual Article: Brodalumab Is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update
October 2023 | Volume 22 | Issue 10 | Supplement Individual Articles | SF378632s5 | Copyright © October 2023
Psoriasis remains a highly prevalent condition in the United States and worldwide. Preclinical research has been triumphant in elucidating the critical immunological pathways involved in psoriasi...
Read MoreMechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases
October 2023 | Volume 22 | Issue 10 | Original Article | 994 | Copyright © October 2023
Biologic therapy is used for systemic treatment of multiple inflammatory conditions, including moderate-to-severe plaque psoriasis. Brodalumab is an interleukin-17 (IL-17) receptor A antagonist indica...
Read MoreDiagnosis and Management of Pediatric Psoriasis: An Overview for Pediatricians
August 2023 | Volume 22 | Issue 8 | Original Article | 742 | Copyright © August 2023
Pediatric psoriasis (PsO) and its associated comorbidities carry physical and psychosocial burdens in children and adolescents, which can negatively impact quality of life. However, features dist...
Read MorePsoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 773 | Copyright © August 2023
Background: Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies. St...
Read MoreJuvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab
August 2023 | Volume 22 | Issue 8 | Case Reports | 830 | Copyright © August 2023
Pemphigus foliaceus is an autoimmune blistering disease of the skin that is not frequently associated with mucous membrane involvement. It is characterized by immunoglobulin G (IgG) antibodies ag...
Read MoreThe Overview of the Immunobiology of Interleukin-23 Associated With Immune-Mediated Inflammatory Disorders: A Narrative Review
April 2023 | Volume 22 | Issue 4 | Original Article | 375 | Copyright © April 2023
Background: Interleukin (IL)-23, a member of the IL-12 family, has emerged as an important cytokine that bridges the innate and adaptive immune systems and plays a critical role ...
Read MoreBrodalumab: 4-Year US Pharmacovigilance Report
April 2023 | Volume 22 | Issue 4 | Features | 419 | Copyright © April 2023
Media and other results for: "ustekinumab"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
